Literature DB >> 15980950

Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment.

Ryo Yamamoto1, Yasushi Otsuka, Masaaki Nakayama, Yukio Maruyama, Naohiko Katoh, Masato Ikeda, Hiroyasu Yamamoto, Keitaro Yokoyama, Yoshindo Kawaguchi, Masato Matsushima.   

Abstract

BACKGROUND: The present study was conducted to clarify the clinical risk factors related to the development of encapsulating peritoneal sclerosis (EPS), which is one of the most serious complications in patients undergoing peritoneal dialysis (PD).
METHODS: The records of 78 patients with a history of PD treatment, including 18 with EPS, were retrospectively analyzed (male/female, 51:27; age, 51.8 +/- 11.0 years; PD treatment, 94.1 +/- 42.7 months). The inclusion criteria were: duration of PD more than 24 months; 36-month follow up after discontinuation of PD; available data for dialysate-to-plasma creatinine ratio (D/P Cr), by fast peritoneal equilibration test within 3 months before PD discontinuation; and absence of EPS at PD discontinuation. Analytical parameters included age, sex, underlying renal disease, duration of PD, membrane transport state (higher transporter or lower transporter: D/P cr ratio more than or less than 0.75), number of episodes of peritonitis during PD treatment, performance of peritoneal lavage after PD discontinuation, and reasons for PD withdrawal (ultrafiltration failure, acute peritonitis, social matters).
RESULTS: Significant differences were noted regarding the PD duration, D/P cr, higher membrane transport state, and number of peritonitis episodes during PD. On receiver operating characteristic curves, the cutoff points for EPS were: D/P cr ratio, 0.74; number of peritonitis episodes, 2; and PD duration (months), 115.2. Multivariate analysis, employing the factors age, PD duration, higher membrane transport state, and number of peritonitis episodes, which were selected by stepwise analysis, identified the latter two factors as significant for the development of EPS (odds ratio [OR], 4.0; P = 0.046 and OR, 12.0; P = 0.049, respectively).
CONCLUSIONS: A higher transporter membrane state and the number of peritonitis episodes are factors contributing to the occurrence of EPS in patients who have experienced PD treatment.

Entities:  

Mesh:

Year:  2005        PMID: 15980950     DOI: 10.1007/s10157-005-0349-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  24 in total

1.  The greater incidence of encapsulating peritoneal sclerosis is not the result of overdiagnosis.

Authors:  M Nakayama
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

Review 2.  Peritoneal sclerosis: one or two nosological entities?

Authors:  G Garosi; N Di Paolo
Journal:  Semin Dial       Date:  2000 Sep-Oct       Impact factor: 3.455

3.  High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment.

Authors:  Ryo Yamamoto; Masaaki Nakayama; Toshio Hasegawa; Numata Miwako; Hiroyasu Yamamoto; Keitaro Yokoyami; Masato Ikeda; Naohiko Kato; Hiroshi Hayakawa; Hajime Takahashi; Yasushi Otsuka; Yoshindo Kawaguchi; Tastuo Hosoya
Journal:  Adv Perit Dial       Date:  2002

4.  Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study.

Authors:  Hideki Kawanishi; Yoshindo Kawaguchi; Hiroyoshi Fukui; Shigeko Hara; Akio Imada; Hitoshi Kubo; Masao Kin; Masahiko Nakamoto; Seiji Ohira; Takao Shoji
Journal:  Am J Kidney Dis       Date:  2004-10       Impact factor: 8.860

5.  Sclerosing peritonitis: the experience in Australia.

Authors:  R J Rigby; C M Hawley
Journal:  Nephrol Dial Transplant       Date:  1998-01       Impact factor: 5.992

6.  Sclerosing obstructive peritonitis after CAPD.

Authors:  D G Oreopoulos; R Khanna; G Wu
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

Review 7.  Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability.

Authors:  D Zemel; R T Krediet
Journal:  Blood Purif       Date:  1996       Impact factor: 2.614

8.  Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.

Authors:  Y Nomoto; Y Kawaguchi; H Kubo; H Hirano; S Sakai; K Kurokawa
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

9.  Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients.

Authors:  V C Gandhi; H M Humayun; T S Ing; J T Daugirdas; V R Jablokow; S Iwatsuki; W P Geis; J E Hano
Journal:  Arch Intern Med       Date:  1980-09

Review 10.  Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature.

Authors:  I E Afthentopoulos; P Passadakis; D G Oreopoulos; J Bargman
Journal:  Adv Ren Replace Ther       Date:  1998-07
View more
  13 in total

1.  Cocoon abdomen after chronic peritoneal dialysis.

Authors:  Philip Edmundson; Claire Adkins; Bruce Smith
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-26

Review 2.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

3.  Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis.

Authors:  Ichiro Hirahara; Eiji Kusano; Yoshiyuki Morishita; Makoto Inoue; Tetsu Akimoto; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  World J Nephrol       Date:  2016-03-06

Review 4.  Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease.

Authors:  Zia Moinuddin; Angela Summers; David Van Dellen; Titus Augustine; Sarah E Herrick
Journal:  Front Physiol       Date:  2015-01-05       Impact factor: 4.566

5.  Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS.

Authors:  Chin-Chung Tseng; Jin-Bor Chen; I-Kuan Wang; Shang-Chih Liao; Ben-Chung Cheng; An-Bang Wu; Yu-Tzu Chang; Shih-Yuan Hung; Chiu-Ching Huang
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

6.  Risk factors of severe peritoneal sclerosis in chronic peritoneal dialysis patients.

Authors:  Sudabeh Alatab; Iraj Najafi; Gholamreza Pourmand; Mostafa Hosseini; Soroosh Shekarchian
Journal:  Ren Fail       Date:  2016-10-24       Impact factor: 2.606

7.  Transperitoneal administration of dissolved hydrogen for peritoneal dialysis patients: a novel approach to suppress oxidative stress in the peritoneal cavity.

Authors:  Hiroyuki Terawaki; Yoshimitsu Hayashi; Wan-Jun Zhu; Yukie Matsuyama; Tomoyoshi Terada; Shigeru Kabayama; Tsuyoshi Watanabe; Seiichi Era; Bunpei Sato; Masaaki Nakayama
Journal:  Med Gas Res       Date:  2013-07-01

8.  Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients.

Authors:  Mitsuhiro Tawada; Yasuhiko Ito; Chieko Hamada; Kazuho Honda; Masashi Mizuno; Yasuhiro Suzuki; Fumiko Sakata; Takeshi Terabayashi; Yoshihisa Matsukawa; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Yoshifumi Takei
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

9.  Effluent Tenascin-C Levels Reflect Peritoneal Deterioration in Peritoneal Dialysis: MAJOR IN PD Study.

Authors:  Ichiro Hirahara; Eiji Kusano; Toshimi Imai; Yoshiyuki Morishita; Makoto Inoue; Tetsu Akimoto; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Biomed Res Int       Date:  2015-12-06       Impact factor: 3.411

10.  Combined surgical and immunosupressive therapy for encapsulating peritoneal sclerosis.

Authors:  P K Bipi; N Gracious; S Kumar; J George
Journal:  Indian J Nephrol       Date:  2016 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.